Table 1.
Average ± standard deviation test characteristics for inferring glioblastoma genetic biomarkers.
| Biomarker | Prev | Sens | Spec | Prec | Recall | F1 | MCC | AUC |
|---|---|---|---|---|---|---|---|---|
| ATRX | 19/190 | 0.94 ± 0.07 | 0.92 ± 0.04 | 0.60 ± 0.12 | 0.94 ± 0.07 | 0.73 ± 0.08 | 0.71 ± 0.08 | 0.97 ± 0.02 |
| IDH | 18/195 | 0.93 ± 0.08 | 0.88 ± 0.07 | 0.50 ± 0.24 | 0.93 ± 0.08 | 0.62 ± 0.16 | 0.62 ± 0.16 | 0.95 ± 0.03 |
| 7/10 aneuploidy | 47/67 | 0.90 ± 0.09 | 0.88 ± 0.08 | 0.95 ± 0.04 | 0.90 ± 0.09 | 0.92 ± 0.06 | 0.75 ± 0.18 | 0.93 ± 0.06 |
| CDKN2 | 41/69 | 0.76 ± 0.06 | 0.86 ± 0.09 | 0.90 ± 0.06 | 0.76 ± 0.06 | 0.82 ± 0.04 | 0.62 ± 0.08 | 0.85 ± 0.04 |
| EGFR | 80/189 | 0.66 ± 0.06 | 0.68 ± 0.10 | 0.61 ± 0.07 | 0.66 ± 0.06 | 0.63 ± 0.05 | 0.34 ± 0.10 | 0.70 ± 0.06 |
| TERT | 64/83 | 0.77 ± 0.15 | 0.59 ± 0.14 | 0.86 ± 0.03 | 0.77 ± 0.15 | 0.81 ± 0.09 | 0.36 ± 0.15 | 0.65 ± 0.08 |
| PTEN | 106/191 | 0.63 ± 0.09 | 0.66 ± 0.09 | 0.70 ± 0.04 | 0.63 ± 0.09 | 0.65 ± 0.04 | 0.28 ± 0.05 | 0.64 ± 0.03 |
| TP53 | 112/186 | 0.57 ± 0.14 | 0.59 ± 0.13 | 0.44 ± 0.05 | 0.57 ± 0.14 | 0.49 ± 0.06 | 0.16 ± 0.08 | 0.57 ± 0.05 |
| MGMT | 140/190 | 0.56 ± 0.07 | 0.56 ± 0.11 | 0.52 ± 0.06 | 0.56 ± 0.07 | 0.53 ± 0.04 | 0.12 ± 0.10 | 0.55 ± 0.07 |
Prevalence (Prev.) refers to the genetic biomarker prevalence in the study cohort. Test characteristics for the best point on the ROC curve (i.e. closest to [0,1]) include sensitivity (Sens.), specificity (Spec.), precision (Prec.), recall, F1 statistic (F1), Matthew’s correlation coefficient (MCC), and the ROC AUC (AUC).